@article{a26a1763641a43fdb81ace6d888a6683,
title = "Bimatoprost: A unique compound that in its nonhydrolyzed form is a prostamide and hydrolyzed form has prostaglandin receptor activity, for glaucoma and cosmetic indications",
abstract = "For over a decade bimatoprost has been available to use for reducing intraocular pressure (IOP). Bimatoprost is available as a single agent in two different concentrations for reducing IOP and also in a fixed-combination with timolol. It is also being evaluated for a sustained-release drug for reducing IOP, and, additionally, it has broadened application potential for cosmetic indications, including enhancing eyelash growth. Despite significant competitive market pressure from other prostanoid drugs on the market, bimatoprost grew to become a commonly used glaucoma drug. Many eye care providers feel, and studies support, bimatoprost is as strong or stronger in its effect in reducing IOP for glaucoma patients.",
keywords = "Bimatoprost, Diurnal IOP, Eyelash growth, Fixed-combination of bimatoprost/timolol, Glaucoma medication, IOP fluctuation, Periorbital pigmentation, Periorbital prostaglandin-associated fat loss, Prostaglandin analog, Prostamide",
author = "Craven, {E. Randy} and Alzuhairy, {Sultan A.}",
note = "Funding Information: Adding timolol to many of glaucoma drops, such as dorzolamide, brinzolamide or brimonidine, increases the tolerability, reduces the number of drops needed and improves hyperemia, allergy or comfort [70]. Meta-analysis studies confirmed this for bimatoprost fixed-combination with timolol (bimatoprost/ timolol fixed combination [BTFC] [GanfortTM bimatoprost 0.03%/timolol 0.5%, Allergan, Inc, Irvine, CA, USA]) [71]. Hommer reported on a double-masked randomized trial comparing the fixed combination of bimatoprost 0.03% with timolol 0.5% to the nonfixed adjunctive individual monotherapy agents used as a combination for OAG/OHTN patients with elevated IOP. The fixed combination had comparable ocular hypotensive reduction and a much lower incidence of hyperemia. This, again, supported a reduction in hyperemia and increased tolerability [72]. A smaller study looking at BTFC to bimatoprost 0.03% alone showed IOP reduction from baseline was 30.2% for bimatoprost and 39.9% for the BTFC. There was less IOP fluctuation with the fixed combination that also provided an additional statistically significant reduction in IOP compared with bimatoprost 0.03% [73]. This was supported by other studies [74]. Copyright: Copyright 2014 Elsevier B.V., All rights reserved.",
year = "2014",
month = jun,
doi = "10.1586/17469899.2014.917959",
language = "English (US)",
volume = "9",
pages = "159--173",
journal = "Expert Review of Ophthalmology",
issn = "1746-9899",
publisher = "Taylor and Francis Ltd.",
number = "3",
}